Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL352555 | 1.00 | LMNA (0.65) | LMNAMAPK1SRCHIF1ATSHR | |
| SCHEMBL467741 | 1.00 | LMNA (0.65) | LMNAMAPK1SRCHIF1ATSHR | |
| SCHEMBL31484031 | 1.00 | LMNA (0.65) | LMNAMAPK1SRCHIF1ATSHR | |
| SCHEMBL5336172 | 0.98 | LMNA (0.62) | LMNAMAPK1SRCHIF1ATSHR | |
| SCHEMBL7522519 | 0.98 | LMNA (0.62) | LMNAMAPK1SRCHIF1ATSHR | |
| Water SCHEMBL564812 | 0.98 | LMNA (0.62) | LMNAMAPK1SRCHIF1ATSHR | |
| SCHEMBL10954019 | 0.98 | LMNA (0.62) | LMNAMAPK1SRCHIF1ATSHR | |
| Ammonia Solution, Strong SCHEMBL7530577 | 0.98 | LMNA (0.62) | LMNAMAPK1SRCHIF1ATSHR | |
| SCHEMBL5088395 | 0.98 | LMNA (0.62) | LMNAMAPK1SRCHIF1ATSHR | |
| SCHEMBL10957256 | 0.98 | LMNA (0.62) | LMNAMAPK1SRCHIF1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080248493-A1 | ACRIDINIUM PHENYL ESTERS USEFUL IN THE ANALYSIS OF BIOLOGICAL SAMPLES | ABBOTT LABORATORIES | 2008-10-09 | — | — | US | claimed |
| CN-1725991-A | Delivery of peroxide producing enzymes to the vagina | KIMBERLY CLARK CO (US) | 2006-01-25 | — | — | CN | claimed |
| EP-1578317-A2 | DELIVERY OF PEROXIDE-GENERATING ENZYMES TO THE VAGINAL TRACT | Kimberly-Clark Worldwide, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2004060272-A2 | DELIVERY OF PEROXIDE-GENERATING ENZYMES TO THE VAGINAL TRACT | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2004-07-22 | — | — | WO | claimed |
| US-20040126369-A1 | Delivery of peroxide-generating enzymes to the vaginal tract | KIMBERLY-CLARK WORLDWIDE, INC. | 2004-07-01 | — | — | US | claimed |
| US-12558329-B2 | Methods and compositions for treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-related diseases or disorders | NEW YORK UNIVERSITY (US) | 2026-02-24 | — | — | US | disclosed |
| US-20240130987-A1 | METHODS AND COMPOSITIONS FOR TREATING 4- HYDROXYPHENYLPYRUVATE DIOXYGENASE-LIKE (HPDL)-RELATED DISEASES OR DISORDERS | NEW YORK UNIVERSITY (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117737020-A | Method for producing p-hydroxyphenylethanol | 杭州唯铂莱生物科技有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-112921012-B | Corynebacterium glutamicum meso-2, 6-diaminopimelate dehydrogenase mutant and application thereof | 江南大学 | 2022-10-11 | — | — | CN | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20190192691-A1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS, INC. | 2019-06-27 | — | — | US | disclosed |
| WO-1997002284-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRA AKTIEBOLAG (SE) | 1997-01-23 | — | — | WO | disclosed |
| US-5004754-A | Biofungicidal composition | UNIVERSITE LAVAL (CA) | 1991-04-02 | — | — | US | disclosed |
| EP-0338499-A2 | Stabilized highly unsaturated fatty acids and derivatives of such acids | NABISCO BRANDS, INC. (US) | 1989-10-25 | — | — | EP | disclosed |
| EP-0153418-A1 | MANDELIC ACID DERIVATIVES | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1985-09-04 | — | — | EP | disclosed |
| US-4297489-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1981-10-27 | — | — | US | disclosed |
| US-4172196-A | CEPHALOSPORINS | BRISTOL-MYERS COMPANY (US) | 1979-10-23 | — | — | US | disclosed |
| US-4112228-A | BACTERICIDES | BRISTOL-MYERS COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-3985738-A | ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12558329-B2 | Methods and compositions for treating 4-hydroxyphenylpyruvate dioxygenase-like (HPDL)-related diseases or disorders | HPD, PGD, SLC25A11 | LMNA 1740/4885MAPK1 4050/4885SRC 4843/4885 |
| US-20240130987-A1 | METHODS AND COMPOSITIONS FOR TREATING 4- HYDROXYPHENYLPYRUVATE DIOXYGENASE-LIKE (HPDL)-RELATED DISEASES OR DISORDERS | HPD, CYP27B1, CYP27A1 | LMNA 1881/4885MAPK1 3564/4885SRC 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.